WALD logo

Waldencast plc Stock Price

NasdaqCM:WALD Community·US$223.7m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

WALD Share Price Performance

US$1.76
-0.76 (-30.16%)
US$3.00
Fair Value
US$1.76
-0.76 (-30.16%)
41.3% undervalued intrinsic discount
US$3.00
Fair Value
Price US$1.76
AnalystHighTarget US$3.00
AnalystLowTarget US$1.60
AnalystConsensusTarget US$2.28

WALD Community Narratives

·
Fair Value US$3 41.3% undervalued intrinsic discount

Rising Global Wealth And Clean Beauty Will Fuel Growth

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$1.6 10.0% overvalued intrinsic discount

Economic, Supply Challenges Will Restrict Beauty Demand Yet Spark Recovery

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$2.28 22.6% undervalued intrinsic discount

Expansion Into Ulta Beauty Stores Will Boost Future Success

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$3
41.3% undervalued intrinsic discount
Profit Margin
8.03%
Future PE
18.58x
Price in 2029
US$3.89
US$1.6
10.0% overvalued intrinsic discount
Profit Margin
8.09%
Future PE
11.56x
Price in 2029
US$2.11

Trending Discussion

Updated Narratives

WALD logo

WALD: Obagi Sale And Injectables Expansion Will Support Future Share Rebound

Fair Value: US$2.28 22.6% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
WALD logo

WALD: Obagi Sale And Injectables Launch Will Support Future Upside

Fair Value: US$3 41.3% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
WALD logo

WALD: Brand Strength And Injectables Expansion Will Drive Future Repricing Despite Higher Costs

Fair Value: US$1.6 10.0% overvalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Adequate balance sheet and slightly overvalued.

2 Risks
0 Rewards

Waldencast plc Key Details

US$272.1m

Revenue

US$89.1m

Cost of Revenue

US$183.0m

Gross Profit

US$412.8m

Other Expenses

-US$229.7m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-1.94
67.27%
-84.44%
27.3%
View Full Analysis

About WALD

Founded
2020
Employees
367
CEO
Michel Brousset
WebsiteView website
www.waldencast.com

Waldencast plc operates in the beauty and wellness industry in the United States, Canada, Europe, the Middle East, India, Australia, and New Zealand. The company operates through two segments, Obagi Medical and Milk Makeup. It offers skin care products to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and protect and enhance skin tone and texture; cosmetics; and other beauty products. In addition, the company provides foundation, concealer, primer, blush, setting spray, and bronzer categories, as well as sells liner, eyeshadow, and lip color products. It serves distributors, retailers, physicians, and directly to consumers through its e-commerce platforms, and third-party logistics and delivery providers. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Recent WALD News & Updates

Narrative Update Jun 29

WALD: Obagi Sale And Injectables Expansion Will Support Future Share Rebound

The analyst price target for Waldencast has been raised from $1.87 to $2.28, with analysts pointing to the announced sale of the Obagi skin care and aesthetics business for up to $460 million as a key factor supporting the higher valuation. What’s in the News for Waldencast Waldencast announced that the U.S. Food and Drug Administration approved Obagi saypha ChIQ injectable hyaluronic acid gel, expanding the Obagi Medical injectable portfolio and targeting cheek augmentation and midface contour correction for patients over 21.
Narrative Update Jun 15

WALD: Obagi Sale And Injectables Launch Will Support Future Upside

Analysts have lifted their price target on Waldencast stock to $3.00 from $2.50, citing the agreed sale of the Obagi skin care and aesthetics business for up to $460m and the view that current valuation does not fully reflect the strength of Obagi, Milk and the upcoming Saypha injectables launch. Analyst Commentary Bullish analysts see the agreed sale of the Obagi skin care and aesthetics business and the ongoing investment in Saypha injectables as key supports for the recent reset to a $3.00 price target.

Recent updates

No updates